FDA: Pregnant Women Should Avoid Valproate Drug for Migraine Prevention

The FDA warns against healthcare providers giving anti-seizure medications valproate sodium, valproic acid and divalproex sodium to pregnant women for migraine prevention, according to the American Society of Anesthesiologists.

Advertisement

FDA warns against valproate use for migraine prevention in pregnant womenA recent study showed these medicines caused lower IQ scores in children when mothers consumed them during pregnancy. Valproate’s pregnancy category will be changed from D, indicating potential benefit despite risks, to X, indicating risk outweighs any possible benefit, according to the report.

Valproate is approved to treat epilepsy, manic episodes associated with bipolar disorder and migraine headache prevention. Pregnant women should completely avoid it for migraines and should only use it for epilepsy or bipolar disorder if other treatments have failed.

More Articles on Anesthesia:
FDA Approves Sedasys Computer-Assisted System for GI Propofol Sedation
Masimo Rainbow Respiratory Monitor Cleared by FDA for Pediatric Use
Anesthesiologists Urge CMS, ONC to Continue Hardship Exemption Through MU Stage 3

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • As the shortage of physician anesthesiologists across the U.S. becomes more severe, certified-registered nurse anesthetists have emerged as an essential…

  • As of April 6, 2026, CRNAs’ average annual salary is $276,434, according to salary transparency platform Marit Health’s compilation of…

Advertisement

Comments are closed.